Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol
when delivered via an SDDPI in patients with COPD. All patients will receive 1 day of
treatment with each of the following: indacaterol 150 µg, once- indacaterol 300 µg,
indacaterol 600 µg, placebo, and formoterol. Each treatment day will be followed by a
washout-period of 1 week.